Results 1 to 10 of about 5,403,461 (136)

Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma [PDF]

Journal of Pathology: Clinical Research, 2022
Siglec‐15, a novel immune checkpoint, is an emerging target for next‐generation cancer immunotherapy. However, the role of Siglec‐15 in pancreatic ductal adenocarcinoma (PDAC) remains poorly understood. We investigated the expression of Siglec‐15 and its
Shuangni Yu, Yue Zhang
exaly   +4 more sources

Non-spatial and spatial heterogeneity revealed a suppressive immune feature of Siglec-15 in lung adenocarcinomas [PDF]

Journal of Translational Medicine, 2023
Background Sialic acid-binding immunoglobulin-like lectin-15 (Siglec-15) has emerged as a novel immunotherapy candidate, which deserves a comprehensive investigation in lung adenocarcinoma (LUAD). Methods Multiplex fluorescence‐based immunohistochemistry
Baihui Li, Yan Guo, Yeran Yi, Ziqi Huang, Yulin Ren, Hao Wang, Lili Yang   +6 more
doaj   +3 more sources

Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma [PDF]

Frontiers in Immunology, 2023
BackgroundSialic acid-binding immunoglobulin-like lectin-15 (Siglec-15) was reported to be a novel immune checkpoint molecule comparable to programmed cell death 1 ligand 1 (PD-L1).
Quan Chen, Quan Chen, Bingkun Chen, Bingkun Chen, Chunhua Wang, Li Hu, Qiongwen Wu, Yanyang Zhu, Qiuyu Zhang, Qiuyu Zhang   +9 more
doaj   +3 more sources

Siglec-15 antibody–GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophages [PDF]

Journal for ImmunoTherapy of Cancer
Background Sialic acid-binding immunoglobulin-like lectin (Siglec)-15-expressing tumor-associated macrophages (TAMs) drive immunosuppression in the tumor microenvironment (TME), promoting CD8+ T cell exhaustion and limiting immunotherapy efficacy.
Jun Li, Hongyan Li, Zemeng Ma, Xiaoyao Hao, Wenwen Dai, Jinyu Liu, Mingjiu Chen, Shuang Qu, Quanli Zhang, Jiajing Luo, Shouyong Gu, Dihan Zhu, Ke Zen   +12 more
doaj   +3 more sources

Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b [PDF]

Nature Communications, 2023
Sialic acid-binding Ig-like lectin 15 (Siglec-15) is an immune modulator and emerging cancer immunotherapy target. However, limited understanding of its structure and mechanism of action restrains the development of drug candidates that unleash its full ...
Maria Pia Lenza, Leire Egia-Mendikute, Asier Antoñana-Vildosola, Cátia O. Soares, Helena Coelho, Francisco Corzana, Alexandre Bosch, Prodhi Manisha, Jon Imanol Quintana, Iker Oyenarte, Luca Unione, María Jesús Moure, Mikel Azkargorta, Unai Atxabal, Klaudia Sobczak, Felix Elortza, James D. Sutherland, Rosa Barrio, Filipa Marcelo, Jesús Jiménez-Barbero, Asis Palazon, June Ereño-Orbea   +21 more
doaj   +3 more sources

The expression characteristic and prognostic role of Siglec‐15 in lung adenocarcinoma [PDF]

The Clinical Respiratory Journal
Sialic acid‐binding immunoglobulin‐like lectin‐15 (Siglec‐15) has been identified as an immune suppressor and a promising candidate for immunotherapy of cancer management.
Haijun Sun, Qilong Du, Yuyu Xu, Cheng Rao, Li Xu, Junrong Yang, Yuan Mao, Lin Wang   +7 more
doaj   +3 more sources

Prognostic value of Siglec-15 expression in patients with solid tumors: A meta-analysis [PDF]

Frontiers in Oncology, 2023
BackgroundSiglec-15 is expressed in a variety of cancers. However, the role of Siglec-15 in the prognosis of cancer patients remains controversial. Therefore, we conducted a meta-analysis to clarify the potential prognostic value of Siglec-15 in solid ...
Kui-Ying Jiang, Li-Li Qi, Li-Li Qi, Xin-Bo Liu, Yong Wang, Ling Wang   +5 more
doaj   +3 more sources

Development of a Novel Anti-Siglec-15 Antibody for Tumor Immunotherapy [PDF]

ImmunoTargets and Therapy
Qin Liu,1,* Lin Li,1,* Siji Nian,1 Xiaoke Sun,2 Xiyuan Guo,1 Chengwen Li,1 Zhihui Yang,3 Yingchun Ye,1 Qing Yuan1,4 1Public Center of Experimental Technology, The School of Basic Medical Sciences, Southwest Medical University, Luzhou ...
Liu Q, Li L, Nian S, Sun X, Guo X, Li C, Yang Z, Ye Y, Yuan Q   +8 more
doaj   +3 more sources

Involvement of Siglec-15 in regulating RAP1/RAC signaling in cytoskeletal remodeling in osteoclasts mediated by macrophage colony-stimulating factor [PDF]

Bone Research
DNAX-associated protein 12 kD size (DAP12) is a dominant immunoreceptor tyrosine-based activation motif (ITAM)-signaling adaptor that activates costimulatory signals essential for osteoclastogenesis.
Hideyuki Kobayashi, M. Alaa Terkawi, Masahiro Ota, Tomoka Hasegawa, Tomomaya Yamamoto, Tomohiro Shimizu, Dai Sato, Ryo Fujita, Toshifumi Murakami, Norio Amizuka, Norimasa Iwasaki, Masahiko Takahata   +11 more
doaj   +3 more sources

Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes [PDF]

Frontiers in Immunology, 2023
Siglecs are well known immunotherapeutic targets in cancer. Current checkpoint inhibitors have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as Siglec-15. Presently, small molecule inhibitors targeting Siglec-15 are
Mohammed Saqif Ahmad, Maria Braoudaki, Hershna Patel, Irshad Ahmad, Shagufta, Shoib Sarwar Siddiqui   +5 more
doaj   +3 more sources